 | |
| Clinical data | |
|---|---|
| Other names | 3,4-Methylenedioxy-α-ethylbenzylamine; 1-Amino-1-(3,4-methylenedioxyphenyl)propane |
| Routes of administration | Oral[1] |
| Drug class | Unknown[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | ~3 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C10H13NO2 |
| Molar mass | 179.219 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
ALPHA, also known as3,4-methylenedioxy-α-ethylbenzylamine, is apsychoactive drug of thesubstituted benzylamine group and apositional isomer of3,4-methylenedioxyamphetamine (MDA).[1][2] It is also a benzylamineanalogue of3,4-methylenedioxyamphetamine (MDA).[1][2] ALPHA was firstsynthesized byAlexander Shulgin.[1][2] In his bookPIHKAL on the MDA page, the threshold dosage is listed as 10 mg.[1] At mild threshold dosages (around 10 mg) there are eyes-closed "dreams" with some body tingling, at higher doses (up to 140 mg) was reported to produce a pleasant, positive feeling.[1] This compound is notanoretic at any dose.[1] Itsduration is about 3 hours.[1] Very little data exists about thepharmacological properties,metabolism, andtoxicity of ALPHA.[1][2] The drug was encountered as a noveldesigner drug by 1996.[3][4]
 | Thispsychoactive drug-related article is astub. You can help Wikipedia byexpanding it. |
